Cargando…

Disruption of TWIST1-RELA binding by mutation and competitive inhibition to validate the TWIST1 WR domain as a therapeutic target

BACKGROUND: Most cancer deaths result from tumor cells that have metastasized beyond their tissue of origin, or have developed drug resistance. Across many cancer types, patients with advanced stage disease would benefit from a novel therapy preventing or reversing these changes. To this end, we hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Roberts, Cai M., Shahin, Sophia A., Loeza, Joana, Dellinger, Thanh H., Williams, John C., Glackin, Carlotta A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345230/
https://www.ncbi.nlm.nih.gov/pubmed/28283022
http://dx.doi.org/10.1186/s12885-017-3169-9
_version_ 1782513675115954176
author Roberts, Cai M.
Shahin, Sophia A.
Loeza, Joana
Dellinger, Thanh H.
Williams, John C.
Glackin, Carlotta A.
author_facet Roberts, Cai M.
Shahin, Sophia A.
Loeza, Joana
Dellinger, Thanh H.
Williams, John C.
Glackin, Carlotta A.
author_sort Roberts, Cai M.
collection PubMed
description BACKGROUND: Most cancer deaths result from tumor cells that have metastasized beyond their tissue of origin, or have developed drug resistance. Across many cancer types, patients with advanced stage disease would benefit from a novel therapy preventing or reversing these changes. To this end, we have investigated the unique WR domain of the transcription factor TWIST1, which has been shown to play a role in driving metastasis and drug resistance. METHODS: In this study, we identified evolutionarily well-conserved residues within the TWIST1 WR domain and used alanine substitution to determine their role in WR domain-mediated protein binding. Co-immunoprecipitation was used to assay binding affinity between TWIST1 and the NFκB subunit p65 (RELA). Biological activity of this complex was assayed using a dual luciferase assay system in which firefly luciferase was driven by the interleukin-8 (IL-8) promoter, which is upregulated by the TWIST1-RELA complex. Finally, in order to inhibit the TWIST1-RELA interaction, we created a fusion protein comprising GFP and the WR domain. Cell fractionation and proteasome inhibition experiments were utilized to elucidate the mechanism of action of the GFP-WR fusion. RESULTS: We found that the central residues of the WR domain (W190, R191, E193) were important for TWIST1 binding to RELA, and for increased activation of the IL-8 promoter. We also found that the C-terminal 245 residues of RELA are important for TWIST1 binding and IL-8 promoter activation. Finally, we found the GFP-WR fusion protein antagonized TWIST1-RELA binding and downstream signaling. Co-expression of GFP-WR with TWIST1 and RELA led to proteasomal degradation of TWIST1, which could be inhibited by MG132 treatment. CONCLUSIONS: These data provide evidence that mutation or inhibition of the WR domain reduces TWIST1 activity, and may represent a potential therapeutic modality. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-017-3169-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5345230
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53452302017-03-14 Disruption of TWIST1-RELA binding by mutation and competitive inhibition to validate the TWIST1 WR domain as a therapeutic target Roberts, Cai M. Shahin, Sophia A. Loeza, Joana Dellinger, Thanh H. Williams, John C. Glackin, Carlotta A. BMC Cancer Research Article BACKGROUND: Most cancer deaths result from tumor cells that have metastasized beyond their tissue of origin, or have developed drug resistance. Across many cancer types, patients with advanced stage disease would benefit from a novel therapy preventing or reversing these changes. To this end, we have investigated the unique WR domain of the transcription factor TWIST1, which has been shown to play a role in driving metastasis and drug resistance. METHODS: In this study, we identified evolutionarily well-conserved residues within the TWIST1 WR domain and used alanine substitution to determine their role in WR domain-mediated protein binding. Co-immunoprecipitation was used to assay binding affinity between TWIST1 and the NFκB subunit p65 (RELA). Biological activity of this complex was assayed using a dual luciferase assay system in which firefly luciferase was driven by the interleukin-8 (IL-8) promoter, which is upregulated by the TWIST1-RELA complex. Finally, in order to inhibit the TWIST1-RELA interaction, we created a fusion protein comprising GFP and the WR domain. Cell fractionation and proteasome inhibition experiments were utilized to elucidate the mechanism of action of the GFP-WR fusion. RESULTS: We found that the central residues of the WR domain (W190, R191, E193) were important for TWIST1 binding to RELA, and for increased activation of the IL-8 promoter. We also found that the C-terminal 245 residues of RELA are important for TWIST1 binding and IL-8 promoter activation. Finally, we found the GFP-WR fusion protein antagonized TWIST1-RELA binding and downstream signaling. Co-expression of GFP-WR with TWIST1 and RELA led to proteasomal degradation of TWIST1, which could be inhibited by MG132 treatment. CONCLUSIONS: These data provide evidence that mutation or inhibition of the WR domain reduces TWIST1 activity, and may represent a potential therapeutic modality. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-017-3169-9) contains supplementary material, which is available to authorized users. BioMed Central 2017-03-10 /pmc/articles/PMC5345230/ /pubmed/28283022 http://dx.doi.org/10.1186/s12885-017-3169-9 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Roberts, Cai M.
Shahin, Sophia A.
Loeza, Joana
Dellinger, Thanh H.
Williams, John C.
Glackin, Carlotta A.
Disruption of TWIST1-RELA binding by mutation and competitive inhibition to validate the TWIST1 WR domain as a therapeutic target
title Disruption of TWIST1-RELA binding by mutation and competitive inhibition to validate the TWIST1 WR domain as a therapeutic target
title_full Disruption of TWIST1-RELA binding by mutation and competitive inhibition to validate the TWIST1 WR domain as a therapeutic target
title_fullStr Disruption of TWIST1-RELA binding by mutation and competitive inhibition to validate the TWIST1 WR domain as a therapeutic target
title_full_unstemmed Disruption of TWIST1-RELA binding by mutation and competitive inhibition to validate the TWIST1 WR domain as a therapeutic target
title_short Disruption of TWIST1-RELA binding by mutation and competitive inhibition to validate the TWIST1 WR domain as a therapeutic target
title_sort disruption of twist1-rela binding by mutation and competitive inhibition to validate the twist1 wr domain as a therapeutic target
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345230/
https://www.ncbi.nlm.nih.gov/pubmed/28283022
http://dx.doi.org/10.1186/s12885-017-3169-9
work_keys_str_mv AT robertscaim disruptionoftwist1relabindingbymutationandcompetitiveinhibitiontovalidatethetwist1wrdomainasatherapeutictarget
AT shahinsophiaa disruptionoftwist1relabindingbymutationandcompetitiveinhibitiontovalidatethetwist1wrdomainasatherapeutictarget
AT loezajoana disruptionoftwist1relabindingbymutationandcompetitiveinhibitiontovalidatethetwist1wrdomainasatherapeutictarget
AT dellingerthanhh disruptionoftwist1relabindingbymutationandcompetitiveinhibitiontovalidatethetwist1wrdomainasatherapeutictarget
AT williamsjohnc disruptionoftwist1relabindingbymutationandcompetitiveinhibitiontovalidatethetwist1wrdomainasatherapeutictarget
AT glackincarlottaa disruptionoftwist1relabindingbymutationandcompetitiveinhibitiontovalidatethetwist1wrdomainasatherapeutictarget